Premium
Pfizer Inc (1PFE)
BIT
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-03-04 | Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer | -826,00 | 21,99k | Sale to Issuer | 26,62 | 32,93k | -2,45% |
| 2026-02-27 | Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer | -655,00 | 18,11k | Sale to Issuer | 27,65 | 12,04k | -5,16% |
| 2026-02-25 | Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer | 510,00 | 17,25k | Derivative Exercise and Retained Stock | 33,82 | 12,70k | 4,19% |
| 2026-02-25 | Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer | -17,05k | 117,57k | Derivative Exercise and Sale | 26,92 - 33,82 | 12,70k | - |
| 2026-02-25 | Ms. Payal Sahni BecherChief People Experience Officer & Exec. VP | 1,74k | 58,81k | Derivative Exercise and Retained Stock | 33,82 | 42,30k | 4,29% |
| 2026-02-25 | Ms. Payal Sahni BecherChief People Experience Officer & Exec. VP | -55,15k | 380,34k | Derivative Exercise and Sale | 26,92 - 33,82 | 42,30k | - |
| 2026-02-25 | Mr. Douglas M. LanklerExec. VP & Chief Legal Officer | 3,90k | 131,83k | Derivative Exercise and Retained Stock | 33,82 | 165,26k | 2,42% |
| 2026-02-25 | Mr. Douglas M. LanklerExec. VP & Chief Legal Officer | -119,01k | 820,79k | Derivative Exercise and Sale | 26,92 - 33,82 | 165,26k | - |
| 2026-02-25 | Dr. Albert BourlaChairman of the Board & CEO | 16,08k | 543,89k | Derivative Exercise and Retained Stock | 33,82 | 394,67k | 4,25% |
| 2026-02-25 | Dr. Albert BourlaChairman of the Board & CEO | -475,54k | 3,28M | Derivative Exercise and Sale | 26,92 - 33,82 | 394,67k | - |
| 2026-02-25 | Ms. Lidia L. FonsecaInitié | 1,76k | 59,66k | Derivative Exercise and Retained Stock | 33,82 | 46,46k | 3,95% |
| 2026-02-25 | Ms. Lidia L. FonsecaInitié | -55,12k | 380,18k | Derivative Exercise and Sale | 26,92 - 33,82 | 46,46k | - |
| 2026-02-25 | Mr. Michael McDermottExec. VP and Chief Global Supply & Quality Officer | -37,93k | 261,35k | Derivative Exercise and Sale | 26,92 - 33,82 | 74,31k | - |
| 2026-02-26 | Mr. Michael McDermottExec. VP and Chief Global Supply & Quality Officer | -2,30k | 62,36k | Sale to Issuer | 27,10 | 74,31k | -3,00% |
| 2026-02-25 | Dr. Chris BoshoffChief Scientific Officer and President of Research & Development | -6,83k | 185,11k | Sale to Issuer | 27,09 | 162,09k | -4,05% |
| 2026-02-23 | Dr. Chris BoshoffChief Scientific Officer and President of Research & Development | -816,00 | 22,08k | Sale to Issuer | 27,06 | 155,54k | -0,52% |
| 2026-02-23 | Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer | -419,00 | 11,34k | Sale to Issuer | 27,06 | 12,19k | -3,32% |
| 2026-01-30 | Dr. Chris BoshoffChief Scientific Officer and President of Research & Development | -12,89k | 340,73k | Sale to Issuer | 26,44 | 156,34k | -7,62% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
